Subscribe
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Special Issues
2020 Year in Review - Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
Cholangiocarcinoma Year in Review Introduction
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
As a result of the COVID-19 pandemic, year 2020 has witnessed unprecedented changes in the practice of medicine. The effect on medical conferences has been equally dramatic, and several major meetings have been canceled or altered. Fortunately, the oncology community adapted quickly!
Read More
A Meta-Analysis of Novel Therapeutics for CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Meta-analysis identifies upregulation of several novel genes that have not been previously described, and suggests the potential role of ERBB2 and extracellular genes in the pathogenesis of CCA.
Read More
Dose-Expansion Portion of Phase 1 Study of E7090 in Patients with CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Interim analysis of the part 2 dose-expansion portion of an ongoing 2-part phase 1 Japanese study shows that the FGFR1 tyrosine kinase inhibitor E7090 was active with a manageable safety profile in CCA patients with FGFR2 gene fusion.
Read More
Hepatocyte-Derived Intrahepatic CCA Requires YAP and SOX9
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
AKT and NOTCH intracellular domain (NICD) targets YAP and SOX9 might be potential targets for therapeutic intervention in intrahepatic CCA subsets, while cholestatic injury or NASH might induce hepatocyte-to-cholangiocyte reprogramming that increases risk of intrahepatic CCA.
Read More
Phase 2 Study of Copanlisib plus Gemcitabine and Cisplatin in Advanced CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Preliminary results of a phase 2 study suggest that the addition of the PI3K inhibitor copanlisib to chemotherapy in the first-line setting was not associated with survival benefit in patients with advanced CCA.
Read More
CXCR2+ Granulocytic Myeloid-Derived Suppressor Cells with the Development of CCA: A Possible Target for Intervention
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Preclinical data implicate the ELR+ chemokine/CXCR2 axes in the pathogenesis of CCA, warranting further studies to define its role in CCA.
Read More
NTRK Gene Fusions in Biliary Tract Cancers
Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Molecular analyses of biliary tract cancers indicate that neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare, suggesting that it is not a major driver of BTC pathogenesis.
Read More
Neoadjuvant Chemoradiation and Orthotopic Liver Transplantation versus Definitive Chemoradiation in Unresectable CCA
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Data reported at the ASCO 2020 GI Cancers Symposium indicate that treatment with neoadjuvant definitive chemoradiation followed by orthotopic liver transplantation was associated with better outcomes compared with definitive chemoradiation alone in patients with unresectable extrahepatic/hilar CCA.
Read More
Reduction of Tumor Burden, Promotion of Hepatic Progenitor-Cell Differentiation, and Induction of Antitumor Immunity in Intrahepatic CCA with Ivosidenib, a Selective IDH1 Inhibitor
Cholangiocarcinoma
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
Preclinical evidence using an genetically engineered mouse model of IDH1-mutated intrahepatic CCA indicates that the selective IDH1 inhibitor ivosidenib mediates its antitumor activity by promoting hepatic progenitor-cell differentiation, and inducing T-cell–mediated antitumor immune response.
Read More
Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
Biliary Tract Cancer
2020 Year in Review: Cholangiocarcinoma
— December 19, 2020
First results of the multicohort phase 2 LEAP-005 study suggest that lenvatinib plus pembrolizumab combination immunotherapy has promising antitumor activity in patients with biliary tract cancer.
Read More
Page 1 of 4
1
2
3
4
View the Latest Issue of CCA News
Read Issue
Home
Issues
Latest Issue
Issue Archive
Special Issues
Online First
Web Exclusives
All Web Exclusives
Videos
Monthly Minutes
Conversations on CCA
Interview with the Innovators
Press Releases
CCA Summit
Cholangiocarcinoma Summit
Subscribe Today!
To sign up for our newsletter or print publications, please enter your contact information below.
I'd like to receive:
CCA News
Print Edition
CCA News
Weekly e‑Newsletter
-- Please Select --
Afghanistan
Åland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua and Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia, Plurinational State of
Bonaire, Sint Eustatius and Saba
Bosnia and Herzegovina
Botswana
Bouvet Island
Brazil
British Indian Ocean Territory
Brunei Darussalam
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo
Congo, the Democratic Republic of the
Cook Islands
Costa Rica
Côte d'Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands (Malvinas)
Faroe Islands
Fiji
Finland
France
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Heard Island and McDonald Islands
Holy See (Vatican City State)
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran, Islamic Republic of
Iraq
Ireland
Isle of Man
Israel
Italy
Jamaica
Japan
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Korea, Democratic People's Republic of
Korea, Republic of
Kuwait
Kyrgyzstan
Lao People's Democratic Republic
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia, the former Yugoslav Republic of
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia, Federated States of
Moldova, Republic of
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territory, Occupied
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Russian Federation
Rwanda
Saint Barthélemy
Saint Helena, Ascension and Tristan da Cunha
Saint Kitts and Nevis
Saint Lucia
Saint Martin (French part)
Saint Pierre and Miquelon
Saint Vincent and the Grenadines
Samoa
San Marino
Sao Tome and Principe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Singapore
Sint Maarten (Dutch part)
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia and the South Sandwich Islands
South Sudan
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syrian Arab Republic
Taiwan, Province of China
Tajikistan
Tanzania, United Republic of
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad and Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States
United States Minor Outlying Islands
Uruguay
Uzbekistan
Vanuatu
Venezuela, Bolivarian Republic of
Viet Nam
Virgin Islands, British
Virgin Islands, U.S.
Wallis and Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
I have reviewed and consent to the terms of
CCA News
's
Privacy Policy
, and
CCA News
has my permission to retain my information in its database, and to forward pertinent communications to me.
START YOUR SUBSCRIPTION